Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Newsoara Ok’d to Start China Phase III Trial of Bowel Function Drug

publication date: May 6, 2022

Shanghai Newsoara Biopharma has been cleared to proceed with its China Phase III trial of LB1148, which is designed to accelerate the return of bowel function in adult patients following bowel/abdominal surgery. The candidate is an oral broad-spectrum serine protease inhibitor that is aimed at neutralizing digestive proteases released from the gut during surgery. Newsoara in-licensed greater China rights to the drug from Palisade Bio of Carlsbad, CA, which recently announced US approval of a similar Phase III trial. Newsoara is a Shanghai in-licensing company with an R&D facility in Suzhou BioBay. More details....

Stock Symbol: (NSDQ: PALI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital